- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01212471
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
September 2, 2020 updated by: Bausch & Lomb Incorporated
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
840
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Irvine, California, United States, 92618
- ISTA Pharmaceuticals, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be of either gender and any race 18 years or older
Exclusion Criteria:
- Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bromfenac Ophthalmic Solution A
Bromfenac ophthalmic solution A
|
sterile ophthalmic solution
|
Experimental: Bromfenac Ophthalmic Solution B
Bromfenac ophthalmic solution B
|
sterile ophthalmic solution
|
Placebo Comparator: Placebo Comparator
|
sterile ophthalmic solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Ocular Surface Disease Index (OSDI) Total Score
Time Frame: 42 days
|
The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire.
Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'.
The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
September 28, 2010
First Submitted That Met QC Criteria
September 29, 2010
First Posted (Estimate)
September 30, 2010
Study Record Updates
Last Update Posted (Actual)
September 4, 2020
Last Update Submitted That Met QC Criteria
September 2, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Ophthalmic Solutions
- Pharmaceutical Solutions
- Bromfenac
Other Study ID Numbers
- S00007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
University of Alabama at BirminghamCompletedContact Lens Wearers With Dry Eye SyndromeUnited States
Clinical Trials on Bromfenac Ophthalmic Solution A
-
Melissa ToyosBausch & Lomb IncorporatedCompletedInflammation | Cataract | Retinal EdemaUnited States
-
Ophthalmic Consultants of BostonBausch & Lomb IncorporatedUnknownDiabetic Macular EdemaUnited States
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedPain | InflammationUnited States
-
Bausch & Lomb IncorporatedCompletedPain | Inflammation | CataractUnited States
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedPain | InflammationUnited States
-
ONL TherapeuticsActive, not recruitingOpen Angle GlaucomaAustralia, New Zealand
-
Stealth BioTherapeutics Inc.CompletedFuchs' Corneal Endothelial Dystrophy (FCED)United States